What is the medical insurance coverage rate in Adagrasib (Krazati) and analysis of policy differences in different provinces

Adagrasib (Krazati) is an oral targeted drug targeting the KRAS G12C mutation. It is currently not fully included in the medical insurance system in some areas of the country. Therefore, when patients use this drug, the overall medical insurance coverage is low, and in most cases they still need to pay for it out of pocket. The price of drugs is relatively high, which imposes a greater burden on patients with limited economic conditions, which also affects its clinical accessibility to a certain extent.

Different provinces have obvious differences in medical insurance policies. Some economically developed regions or pilot cities may include some imported targeted drugs within the scope of local special drug reimbursement under certain conditions, thereby providing partial cost support. In relatively underdeveloped areas, patients are usually unable to obtain reimbursement through medical insurance and need to purchase drugs entirely at their own expense, which leads to imbalances in drug accessibility and economic burden.

For patients not covered by medical insurance, overseas channels have become an important way to obtain adagrasib. In overseas markets, drugs are divided into two categories: original drugs and generic drugs. Original drugs are more expensive, mostly in the range of tens of thousands of yuan, while generic drugs are more affordable. For example, the generic drug 120mg*56 tablets produced in Laos costs about more than 1,000 yuan, and the drug ingredients are basically the same as the original drug, which provides domestic patients with a relatively economical treatment option.

In the future, with the gradual improvement of domestic targeted drug policies and the advancement of drug negotiation mechanisms, adagrasib is expected to gradually be included in medical insurance coverage. Policy differences across regions may gradually narrow, allowing more patients to access drug treatments at reasonable costs. At the same time, the existence of overseas generic drugs also provides patients with viable alternatives, easing economic pressure and improving drug accessibility.

Reference materials:https://www.drugs.com/